Title:
COMBINATION MEDICATION CONTAINING LIPOSOME COMPOSITION ENCAPSULATING DRUG AND IMMUNE CHECKPOINT INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2019/244979
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a medication obtained by combining a liposome composition in which a liposome encapsulates a drug with an immune checkpoint inhibitor. The present invention provides a medication involving concurrent or successive administration of: (A) a liposome composition containing, as constituent components of a liposome film, a cholesterol, dihydrosphingomyelin, diacylphosphatidyl ethanol amine modified with a hydrophilic polymer, wherein the liposome composition encapsulates a drug, the internal water phase thereof contains ammonium sulfate, the molar ratio of the sulfate ions of the internal water phase with respect to the entire water phase drug is 0.36 or more; and (B) an immune checkpoint inhibitor.
More Like This:
Inventors:
SHIMOYAMA SUSUMU (JP)
IOROI TADAAKI (JP)
MORI MIKINAGA (JP)
HIGUCHI TAMAMI (JP)
IOROI TADAAKI (JP)
MORI MIKINAGA (JP)
HIGUCHI TAMAMI (JP)
Application Number:
PCT/JP2019/024500
Publication Date:
December 26, 2019
Filing Date:
June 20, 2019
Export Citation:
Assignee:
FUJIFILM CORP (JP)
International Classes:
A61K9/127; A61K31/404; A61K31/4745; A61K31/704; A61K47/04; A61K47/24; A61K47/28; A61P35/00
Domestic Patent References:
| WO2017078008A1 | 2017-05-11 | |||
| WO2017079303A1 | 2017-05-11 | |||
| WO2018181963A1 | 2018-10-04 | |||
| WO2006121168A1 | 2006-11-16 |
Foreign References:
| JP2017512840A | 2017-05-25 | |||
| JP2006340714A | 2006-12-21 | |||
| US7060828B2 | 2006-06-13 | |||
| US7811602B2 | 2010-10-12 | |||
| JP2008519045A | 2008-06-05 | |||
| JPH02196713A | 1990-08-03 | |||
| JPH02196713A | 1990-08-03 | |||
| US6355268B1 | 2002-03-12 |
Other References:
KYLE D.FUGIT ,BRADLEY D.ANDERSON: "Ion-Pairing Contribution to the Liposomal Transport of Topotecan as Revealed by Mechanistic Modeling", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 106, no. 4, 1 April 2017 (2017-04-01), pages 1149 - 1161, XP009524928, DOI: 10.1016/j.xphs.2016.12.011
"ONO ONCOLOGY Opdivo Q&A, Can Opdivo be used in combination with chemotherapeutic agents?", 2 May 2018, ONO PHARMACEUTICAL CO., LTD.
WILLIAM C. ZAMBONI: "#C113 A Pharmacokinetics Study of a Novel Sphingomyelin/Cholesterol Liposomal Topotecan and Non-Liposomal Topotecan in Rats", AACR-EORTC INTERNATIONAL CONFERENCE, SAN FRANCISCO, CALIFORNIA, 22 October 2007 (2007-10-22)
NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE, vol. 11, 2015, pages 1841 - 1850
See also references of EP 3811931A4
"ONO ONCOLOGY Opdivo Q&A, Can Opdivo be used in combination with chemotherapeutic agents?", 2 May 2018, ONO PHARMACEUTICAL CO., LTD.
WILLIAM C. ZAMBONI: "#C113 A Pharmacokinetics Study of a Novel Sphingomyelin/Cholesterol Liposomal Topotecan and Non-Liposomal Topotecan in Rats", AACR-EORTC INTERNATIONAL CONFERENCE, SAN FRANCISCO, CALIFORNIA, 22 October 2007 (2007-10-22)
NANOMEDICINE: NANOTECHNOLOGY, BIOLOGY, AND MEDICINE, vol. 11, 2015, pages 1841 - 1850
See also references of EP 3811931A4
Attorney, Agent or Firm:
SIKs & Co. (JP)
Download PDF: